Cadrenal Therapeutics Inc CVKD

NAS: CVKD | ISIN: US1276361086 6/05/2024

0,500 USD (+1,94%)

(+1,94%) 6/05/2024

Grafiek Cadrenal Therapeutics Inc

Grafiek Cadrenal Therapeutics Inc

1 dag1d 1,94%
1 week1w 13,64%
1 maand1m -1,96%
3 maanden3m -55,75%
6 maanden6m 19,10%
1 jaar1j -64,79%
5 jaar5j -87,86%

Cadrenal Therapeutics Inc in het nieuws

Toon enkel gratis nieuws

11 april 2024 · Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024 · Persbericht

9 april 2024 · Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts · Persbericht

11 maart 2024 · Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update · Persbericht

26 februari 2024 · Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference · Persbericht

8 februari 2024 · Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial · Persbericht

31 januari 2024 · Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions · Persbericht

24 januari 2024 · Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 · Persbericht

4 januari 2024 · Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference · Persbericht

Aandelen Cadrenal Therapeutics Inc

Beurswaarde: 7,85 miljoen USD

Effecten: 16,01 miljoen

Beta: 0,35

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe